<?xml version="1.0" encoding="UTF-8"?>
<p id="para10">Most patients with newly diagnosed multiple myeloma have achieved survival benefits from the therapeutic advances made during the past decade, but patients with high-risk subsets of disease have benefited less.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> High-risk disease can be identified at presentation by the cytogenetic lesions t(4;14), t(14;16), t(14;20), del(17p), and gain(1q), which are good markers to predict early relapse. In patients with high-risk disease, relapse is the result of the persistence of residual disease,
 <xref rid="bib2" ref-type="bibr">2</xref>, 
 <xref rid="bib3" ref-type="bibr">3</xref> even at very low levels, and is associated with clonal evolution and progressive immune dysfunction.
 <xref rid="bib4" ref-type="bibr">4</xref>, 
 <xref rid="bib5" ref-type="bibr">5</xref> These biological features can impair the activity of subsequent lines of therapy; therefore, finding strategies that could prevent relapse in this group would be a considerable step forward to improve the outcomes of these patients.
 <xref rid="bib6" ref-type="bibr">
  <sup>6</sup>
 </xref>
</p>
